Companies → Vaxcyte, Inc.

Save to list

Remove

Vaxcyte, Inc.

United States, San Carlos

Report a bug?

Claim ownership and edit

Description

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Industries

Wood Product Manufacturing

SIC

Lumber and Wood Products, Except Furniture

Address:

825 Industrial Road

Website:

vaxcyte.com

Recent news:

Kynam Capital Reduces Cogent Biosciences Stake in Q4 2025

Analysis of Kynam Capital Management's Q4 2025 reduction in its Cogent Biosciences position, detailing the $48.38M sale and the biotech firm's current financial and clinical status.

Source: IndexBox Mar 22, 2026

Kynam Capital Reduces Viridian Therapeutics Stake by $81M in Q4 2025

Analysis of Kynam Capital Management's sale of a major portion of its Viridian Therapeutics holdings, detailing the transaction value and the company's current financial standing.

Source: IndexBox Mar 22, 2026

FDA Imposes New Vaccine Restrictions, Moderna Shares Drop

The FDA is tightening vaccine approval rules, requiring additional safety tests. This policy shift under HHS has led to a decline in Moderna's stock and raised concerns for vaccine developers.

Source: IndexBox Dec 1, 2025

Medicxi Raises 500 Million Euros for New Biotech Investment Fund

Medicxi announces €500 million fundraise for biotech investments using asset-centric strategy during biotech venture funding recovery in late 2025.

Source: IndexBox Nov 14, 2025

XNAS - Delayed Quote - USD

PCVX

54.72 +0.74 (+1.37%)

At close March 23 09:00 UTC

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 06/22/2025

Market Cap: 4.24 B

Enterprise Value: 2.66 B

Trailing P/E: N/A

Forward P/E: -6.98

PEG Ratio (5yr expected): N/A

Price/Sales (ttm): N/A

Price/Book (mrq): 1.33

Enterprise Value/Revenue: N/A

Enterprise Value/EBITDA: -4.24

Financial Highlights

Profitability and Income Statement

Profit Margin: N/A%

Return on Assets (ttm): -14.53%

Return on Equity (ttm): -19.66%

Revenue (ttm): N/A

Net Income Avi to Common (ttm): -509.62 M

Diluted EPS (ttm): -3.99

Balance Sheet and Cash Flow

Total Cash (mrq): 1.67 B

Total Debt/Equity (mrq): 2.73%

Levered Free Cash Flow (ttm): -419.13 M

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.